New injection for kids with lupus shows promise in chinese study
NCT ID NCT05917288
First seen Nov 16, 2025 · Last updated May 14, 2026 · Updated 17 times
Summary
This study looked at how a lupus medicine called belimumab works in Chinese children aged 5 to 17 who had already received the IV form for 48 weeks. The goal was to check the drug levels in the blood and see if switching to a shot under the skin is safe. Sixteen children took part, and the results help doctors understand the right dose for different weight groups.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC LUPUS ERYTHEMATOSUS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
GSK Investigational Site
Beijing, 100045, China
-
GSK Investigational Site
Changsha, 410007, China
-
GSK Investigational Site
Hangzhou, 310052, China
-
GSK Investigational Site
Nanjing, 210011, China
-
GSK Investigational Site
Shanghai, 361006, China
-
GSK Investigational Site
Suzhou, 215007, China
Conditions
Explore the condition pages connected to this study.